<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02940249</url>
  </required_header>
  <id_info>
    <org_study_id>GLU-Pomme</org_study_id>
    <nct_id>NCT02940249</nct_id>
  </id_info>
  <brief_title>Effects of an Apple Extract on Glycaemia: The GLU-Pomme Study</brief_title>
  <acronym>GLU-Pomme</acronym>
  <official_title>Dose-response Effect of an Apple Extract on Postprandial Glycaemia: a Randomised Controlled Trial. The GLU-POMME Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DIANA Food</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postprandial hyperglycaemia can lead to adverse modifications to functional proteins within
      the body and eventually lead to the development of type 2 diabetes. Previous research by this
      group has shown that an apple polyphenol extract reduced hyperglycaemia following a
      high-carbohydrate meal. The aim of this study is to investigate the effects of lower doses of
      the apple extract on postprandial glycaemia, insulinaemia and plasma gastric inhibitory
      polypeptide concentrations following a mixed carbohydrate test meal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      Sharp peaks in blood glucose levels can lead to adverse modifications to functional proteins,
      oxidative stress and pancreatic beta cell dysfunction. It is therefore desirable to consume a
      diet that will allow more gradual rises in blood glucose levels after meals. Fruit
      polyphenols may help to limit the glucose excursion following a high carbohydrate meal.
      Previous research by this research group has demonstrated that 1200 mg of apple polyphenols
      (Appl'In™) inhibited the average incremental area under the curve (T+0 to T+30 min) of plasma
      glucose by 54% relative to placebo. Possible mechanisms include inhibition of intestinal
      enzymes and inhibition of intestinal glucose absorption by decreasing SGLT1/GLUT2 transport
      activity. The literature also suggests that foods rich in polyphenols exert beneficial
      effects on risk factors of cardiovascular disease such as hypertension, lipid metabolism and
      vascular function.

      Study design:

      A randomised, controlled, double-blind, cross-over study will be conducted. Four matched test
      drinks will be consumed in random order on separate study visits immediately before a
      mixed-carbohydrate test meal, containing either: 1) 1.2 g, 2) 0.9 g 3). 0.6 g of apple
      polyphenols, or 4). placebo. Postprandial changes in plasma glucose, insulin, NEFA, GIP,
      GLP-1 concentrations as well as changes in vascular function will be measured. Twenty-four
      hour urine samples will be collected for analysis of urinary polyphenol metabolites and
      glucose. In a sub sample of participants, a paracetamol absorption test will be incorporated
      via addition of 1.5 g paracetamol into the test drink.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial Glycaemia</measure>
    <time_frame>30 min following the test drink</time_frame>
    <description>Primary outcome: Area over baseline t+0-30 min for plasma glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial Insulinaemia</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial insulin concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucose-dependent Insulinotropic Polypeptide (GIP) Concentrations</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial GIP concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Glucagon-like Peptide-1 (GLP-1) Concentrations</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial GLP-1 concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial C-peptide Concentrations</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial C-peptide concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Non-esterified Fatty Acid (NEFA) Concentrations</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial NEFA concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Triglyceride (TAG) Concentrations</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial TAG concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Paracetamol Concentrations</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial paracetamol concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min (1.5 g paracetamol will be added to all test drinks in a sub-group of participants).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial Polyphenol Metabolite Concentrations</measure>
    <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
    <description>Peak postprandial polyphenol metabolites concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Endothelial Function by Flow-mediated Dilation (FMD)</measure>
    <time_frame>baseline and 120, 240, 300 min following the test drink</time_frame>
    <description>Change in FMD after the consumption of test drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Function (Arteriograph Measurement)</measure>
    <time_frame>Baseline and 60, 90, 120, 180, 240 min following the test drink</time_frame>
    <description>Change in augmentation index following the test drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline and 60, 90, 120, 180, 240 min following the test drink</time_frame>
    <description>Change in blood pressure following the test drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Polyphenol Metabolites</measure>
    <time_frame>0-4 h, 4-8 h, 8-24 h following the test drink</time_frame>
    <description>Change in urinary polyphenol metabolite concentration following the test drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose</measure>
    <time_frame>0-4 h, 4-8 h, 8-24 h following the test drink</time_frame>
    <description>Change in urinary glucose concentration following the test drink.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>7-day Food Diary</measure>
    <time_frame>Baseline</time_frame>
    <description>Habitual dietary intake analysis</description>
  </other_outcome>
  <other_outcome>
    <measure>Women's Health Questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>Questionnaire to identify menstrual phase</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Prevention of Hyperglycaemia</condition>
  <arm_group>
    <arm_group_label>1.2 g apple polyphenols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200 mg apple polyphenols delivered in a low sugar drink.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9 g apple polyphenols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg apple polyphenols delivered in a low sugar drink.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.6 g apple polyphenols</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg apple polyphenols delivered in a low sugar drink.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No polyphenols delivered in a low sugar drink.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Apple polyphenols</intervention_name>
    <description>Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.</description>
    <arm_group_label>0.6 g apple polyphenols</arm_group_label>
    <arm_group_label>0.9 g apple polyphenols</arm_group_label>
    <arm_group_label>1.2 g apple polyphenols</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-70 y

          -  Male and female

          -  Healthy (free of diagnosed diseases listed in the exclusion criteria)

          -  Body Mass Index 18-35 kg/m2

          -  Able to understand the information sheet and willing to comply with study protocol

          -  Able to give informed written consent

        Exclusion Criteria:

          -  Those diagnosed with Phenylketonuria (PKU)

          -  Those with known or suspected food and/or paracetamol intolerances, allergies or
             hypersensitivity

          -  Women who are known to be pregnant or who are intending to become pregnant over the
             course of the study

          -  Women who are breast feeding

          -  Participation in another clinical trial

          -  Those who have donated blood within 3 months of the screening visit and participants
             for whom participation in this study would result in having donated more than 1500
             millilitres of blood in the previous 12 months.

          -  Full Blood Counts and Liver Function test results outside of the normal range.

          -  Current smokers, or reported giving up smoking within the last 6 months

          -  History of substance abuse or alcoholism

          -  Reported history of Cardiovascular disease, diabetes (or fasting glucose ≥ 7.1
             mmol/L), cancer, kidney, liver or bowel disease, gastrointestinal disorder or use of
             drug likely to alter gastrointestinal function

          -  Unwilling to restrict consumption of specified high polyphenol foods for 48 h before
             the study

          -  Weight change &gt;3kg in preceding 2 months and body mass index &lt;18 or &gt;35 kg/m2

          -  Blood pressure ≥160/100 mmHg

          -  Total cholesterol ≥ 7.5 mmol/L; fasting triacylglycerol concentrations ≥ 5.0 mmol/L

          -  Medications that may interfere with the study: alpha-glucosidase inhibitors (acarbose:
             Glucobay), insulin sensitizing drugs (metformin: Glucophage, Glucophage SR, Eucreas,
             Janumet; thiazolidinediones: Actos, Competact), sulfonylureas (Daonil, Diamicron,
             Diamicron MR, Glibenese, Minodiab, Amaryl Tolbutamide), and lipid lowering drugs
             (statins, nicotinic acid, colestyramine anhydrous, ezetimibe, fibrates); and
             medications that may react unpredictably with paracetamol: ketoconazole,
             metoclopramide, carbamazepine, phenobarbital, phenytoin, primidone, warfarin and other
             products containing paracetamol. Other medications should be reviewed by medical
             representative from KCL on a case by case basis.

          -  Nutritional supplements that may interfere with the study: higher dose
             vitamins/minerals (&gt;200% Recommend Nutrient Intake), B vitamins, Vitamin C, calcium,
             copper, chromium, iodine, iron, magnesium, manganese, phosphorus, potassium and zinc.
             Subjects already taking vitamin or minerals at a dose around 100% or less up to 200%
             of the RNI, or evening primrose/algal/fish oil supplements will be asked to maintain
             habitual intake patterns, ensuring that they take them every day and not sporadically.
             They will be advised not to stop taking supplements or start taking new supplements
             during the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metabolic Research Unit at King's College London</name>
      <address>
        <city>Waterloo Campus</city>
        <state>London</state>
        <zip>SE1 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0955286316301061</url>
    <description>Castro-Acosta et al. (2016). Drinks containing anthocyanin-rich blackcurrant extract decrease postprandial blood glucose, insulin and incretin concentrations. The Journal of Nutritional Biochemistry 38: 154-161.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>October 19, 2016</study_first_submitted>
  <study_first_submitted_qc>October 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2016</study_first_posted>
  <results_first_submitted>January 24, 2020</results_first_submitted>
  <results_first_submitted_qc>June 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 17, 2020</results_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyphenol</keyword>
  <keyword>Apple</keyword>
  <keyword>Fruit</keyword>
  <keyword>Hyperglycaemia</keyword>
  <keyword>Metabolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02940249/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02940249/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy participants were recruited from King’s College London (KCL) and the general public in London and surrounding counties.</recruitment_details>
      <pre_assignment_details>34 out of 64 screened were randomized. Of those not randomized, 8 did not meet inclusion criteria, 1 had a minor adverse event, and 21 declined to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Doses of Apple Extract</title>
          <description>Randomised sequences of singled doses of 0, 0.9, 1.2 and 1.8 g apple extract consumed with a test meal. Participants first received intervention 1 on the morning of a study visit, followed by a washout period of at least 7 days, then intervention 2 followed by a 7 day washout period, then intervention 3 followed by a 7 day washout period, then intervention 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All participants completing all study interventions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Mean (SD) age (years)</description>
          <population>Numbers analyzed in rows differ from overall as they are given for men, postmenopausal women, and premenopausal women separately.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Males</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premenopausal females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal females</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting glucose</title>
          <description>Fasting plasma glucose concentrations (mmol/L)</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.18" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postprandial Glycaemia</title>
        <description>Primary outcome: Area over baseline t+0-30 min for plasma glucose</description>
        <time_frame>30 min following the test drink</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1.8 g Apple Extract</title>
            <description>High dose of polyphenol apple extract in a drink</description>
          </group>
          <group group_id="O2">
            <title>1.2 g Apple Extract</title>
            <description>Medium dose of polyphenol apple extract in a drink</description>
          </group>
          <group group_id="O3">
            <title>0.9 g Apple Extract</title>
            <description>Low dose of apple extract in a drink</description>
          </group>
          <group group_id="O4">
            <title>0 g Apple Extract</title>
            <description>Control in a drink matched for appearance and macronutrients</description>
          </group>
        </group_list>
        <measure>
          <title>Postprandial Glycaemia</title>
          <description>Primary outcome: Area over baseline t+0-30 min for plasma glucose</description>
          <units>mmol/L*min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="1.2"/>
                    <measurement group_id="O2" value="15.2" spread="1.5"/>
                    <measurement group_id="O3" value="17.8" spread="1.6"/>
                    <measurement group_id="O4" value="27.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Insulinaemia</title>
        <description>Peak postprandial insulin concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Glucose-dependent Insulinotropic Polypeptide (GIP) Concentrations</title>
        <description>Peak postprandial GIP concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Glucagon-like Peptide-1 (GLP-1) Concentrations</title>
        <description>Peak postprandial GLP-1 concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial C-peptide Concentrations</title>
        <description>Peak postprandial C-peptide concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Non-esterified Fatty Acid (NEFA) Concentrations</title>
        <description>Peak postprandial NEFA concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Triglyceride (TAG) Concentrations</title>
        <description>Peak postprandial TAG concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Paracetamol Concentrations</title>
        <description>Peak postprandial paracetamol concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min (1.5 g paracetamol will be added to all test drinks in a sub-group of participants).</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postprandial Polyphenol Metabolite Concentrations</title>
        <description>Peak postprandial polyphenol metabolites concentrations (Cmax) t +0-30 min and change from baseline data and areas over baseline t+0-30 min and t+0-240 min.</description>
        <time_frame>baseline and 10, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Endothelial Function by Flow-mediated Dilation (FMD)</title>
        <description>Change in FMD after the consumption of test drink.</description>
        <time_frame>baseline and 120, 240, 300 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Function (Arteriograph Measurement)</title>
        <description>Change in augmentation index following the test drink.</description>
        <time_frame>Baseline and 60, 90, 120, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Change in blood pressure following the test drink.</description>
        <time_frame>Baseline and 60, 90, 120, 180, 240 min following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Polyphenol Metabolites</title>
        <description>Change in urinary polyphenol metabolite concentration following the test drink.</description>
        <time_frame>0-4 h, 4-8 h, 8-24 h following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Glucose</title>
        <description>Change in urinary glucose concentration following the test drink.</description>
        <time_frame>0-4 h, 4-8 h, 8-24 h following the test drink</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>7-day Food Diary</title>
        <description>Habitual dietary intake analysis</description>
        <time_frame>Baseline</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Women's Health Questionnaire</title>
        <description>Questionnaire to identify menstrual phase</description>
        <time_frame>Baseline</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 hour study visit for each of the 4 interventions.</time_frame>
      <desc>Arms/groups for randomised sequence are combined as there are a large number of different sequences.
All-Cause Mortality was not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>1.8 g Apple Extract</title>
          <description>High dose of polyphenol apple extract in a drink</description>
        </group>
        <group group_id="E2">
          <title>1.2 g Apple Extract</title>
          <description>Medium dose of polyphenol apple extract in a drink</description>
        </group>
        <group group_id="E3">
          <title>0.9 g Apple Extract</title>
          <description>Low dose of apple extract in a drink</description>
        </group>
        <group group_id="E4">
          <title>0 g Apple Extract</title>
          <description>Control in a drink matched for appearance and macronutrients</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Wendy Hall</name_or_title>
      <organization>King's College London</organization>
      <phone>020 7836 5454</phone>
      <email>wendy.hall@kcl.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

